Aptamer Group

Aptamer Group is a life sciences company developing synthetic nucleic acid-based affinity binders as high-performance alternatives to antibodies.

Selected via its proprietary SELEX-derived platform, the binders are customised against protein, peptide, cell, and small molecule targets for applications across drug discovery, diagnostic assay development, bioprocessing, and targeted therapeutic delivery.

The company works with all top-ten global pharmaceutical companies and holds royalty-bearing licences across multiple programmes.